Published in Cancer Res on July 15, 1995
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A (1998) 5.74
Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol (1996) 4.67
Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol (2005) 2.55
The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol (1998) 2.53
Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev (2003) 2.32
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol (1999) 1.52
Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci U S A (1997) 1.51
Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol (1999) 1.49
Two overlapping reading frames in a single exon encode interacting proteins--a novel way of gene usage. EMBO J (2001) 1.48
Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry (2011) 1.48
Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol Cell Biol (1997) 1.36
Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A (1996) 1.31
Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol (1999) 1.17
Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene. Invest Ophthalmol Vis Sci (2004) 1.17
CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. Am J Pathol (2001) 1.12
Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol (2002) 1.11
Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol (1997) 1.08
Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest (2009) 1.07
Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol (1996) 1.06
DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer. J Mol Histol (2006) 1.05
Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol (1999) 1.04
CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol (1998) 1.03
Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol (1998) 1.01
Clinical Overview of MDM2/X-Targeted Therapies. Front Oncol (2016) 0.98
Aberrant signaling pathways in glioma. Cancers (Basel) (2011) 0.96
Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. Proc Natl Acad Sci U S A (1997) 0.92
INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol (2000) 0.91
Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol (2014) 0.90
Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg (2011) 0.89
Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer (1997) 0.87
DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours. Br J Cancer (1999) 0.86
Restoration of p16INK4A protein induces myogenic differentiation in RD rhabdomyosarcoma cells. Br J Cancer (1999) 0.85
Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification. J Mol Diagn (2004) 0.85
Cell cycle and no end. Virchows Arch (2004) 0.84
p14(ARF)-induced apoptosis in p53 protein-deficient cells is mediated by BH3-only protein-independent derepression of Bak protein through down-regulation of Mcl-1 and Bcl-xL proteins. J Biol Chem (2012) 0.84
Methylation status of p16 INK4A tumor suppressor gene in Iranian patients with sporadic breast cancer. J Cancer Res Clin Oncol (2009) 0.84
Sequence variation and chromosomal mapping of the murine Cdkn2a tumor suppressor gene. Mamm Genome (1997) 0.81
p14ARF induces the relocation of HDM2 and p53 to extranucleolar sites that are targeted by PML bodies and proteasomes. Mol Cancer (2003) 0.80
Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. Am J Pathol (1997) 0.80
Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival. Oncogene (2015) 0.79
Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts. Br J Cancer (2000) 0.77
Polymorphisms in promoter sequences of MDM2, p53, and p16 genes in normal Japanese individuals. Genet Mol Biol (2010) 0.75
The interplay between p16 serine phosphorylation and arginine methylation determines its function in modulating cellular apoptosis and senescence. Sci Rep (2017) 0.75
Ocular expression and distribution of products of the POAG-associated chromosome 9p21 gene region. PLoS One (2013) 0.75
CDK inhibitors for muscle stem cell differentiation and self-renewal. J Phys Fit Sports Med (2017) 0.75
p53 mutations in human cancers. Science (1991) 31.96
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell (1998) 7.46
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
Head and neck cancer. N Engl J Med (2001) 7.32
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82
Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med (1998) 6.52
Chemokines and disease. Nat Immunol (2001) 5.62
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res (1996) 4.89
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (2000) 4.87
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A (2000) 4.37
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol (1999) 4.15
Mitochondrial DNA mutations in human cancer. Oncogene (2006) 4.08
Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med (2001) 3.96
Language comprehension in language-learning impaired children improved with acoustically modified speech. Science (1996) 3.84
Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature (2000) 3.81
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res (1996) 3.50
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer (2001) 3.22
MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest (1999) 3.21
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18
Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res (1997) 3.17
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res (1993) 2.99
Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med (1996) 2.95
Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst (2001) 2.93
Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother (1990) 2.91
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res (2000) 2.79
Role of the p16 tumor suppressor gene in cancer. J Clin Oncol (1998) 2.51
p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res (2001) 2.34
Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst (1999) 2.34
Wound healing in MIP-1alpha(-/-) and MCP-1(-/-) mice. Am J Pathol (2001) 2.34
Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey. N Engl J Med (1994) 2.22
A new human p53 homologue. Nat Med (1998) 2.21
Influenza virus gene expression: control mechanisms at early and late times of infection and nuclear-cytoplasmic transport of virus-specific RNAs. J Virol (1987) 2.21
Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res (2001) 2.18
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res (1999) 2.17
Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (1994) 2.16
The role of sucrose in cariogenic dental biofilm formation--new insight. J Dent Res (2006) 2.10
Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res (2001) 2.10
Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A (1999) 2.08
Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells. J Biol Chem (1991) 2.06
The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res (1993) 2.05
Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst (2001) 2.04
Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res (1995) 1.99
Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res (2001) 1.98
Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med (1999) 1.94
Fibronectin and proteoglycans as determinants of cell-substratum adhesion. J Supramol Struct (1979) 1.93
Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res (2000) 1.91
High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J Immunol (1995) 1.87
Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (1999) 1.86
Monocyte chemoattractant protein-1. Chem Immunol (1999) 1.85
Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci U S A (1994) 1.81
Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res (1996) 1.80
Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst (1998) 1.78
Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res (1998) 1.71
Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res (2001) 1.71
A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol Cell Biol (1995) 1.68
Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res (1994) 1.68
Biochemical and biologic characterization of murine monocyte chemoattractant protein-1. Identification of two functional domains. J Immunol (1994) 1.67
Serial analysis of gene expression in non-small cell lung cancer. Cancer Res (1998) 1.67
Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene (2001) 1.66
Genetic divergence in the clonal evolution of breast cancer. Cancer Res (1996) 1.63
Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res (2001) 1.63
Infrequent p53 gene mutations in medulloblastomas. Cancer Res (1991) 1.62
Microsatellite instability at AAAG repeat sequences in respiratory tract cancers. Int J Cancer (2001) 1.62
Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J Biol Chem (1994) 1.62
Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest (1999) 1.62
Anterior speech region. Asymmetry and weight-surface correlation. Arch Neurol (1989) 1.61
Diagnosis of renal cancer by molecular urinalysis. J Natl Cancer Inst (1999) 1.60
Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes: abrogation by a second transgene expressing systemic MCP-1. J Immunol (1997) 1.57
Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope (1999) 1.55
Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci U S A (2001) 1.53
Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging (2002) 1.50
MCP-1 expression by rat type II alveolar epithelial cells in primary culture. J Immunol (1993) 1.49
Allelotype of head and neck squamous cell carcinoma. Cancer Res (1994) 1.47
p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol (1998) 1.46
Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res (2000) 1.46
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst (2000) 1.45
Glycosaminoglycans in the substrate adhesion sites of normal and virus-transformed murine cells. Biochemistry (1979) 1.44
Molecular detection of primary bladder cancer by microsatellite analysis. Science (1996) 1.44
Frequent microsatellite instability in primary small cell lung cancer. Cancer Res (1994) 1.44
Autotraction versus passive traction: an open controlled study in lumbar disc herniation. Arch Phys Med Rehabil (1993) 1.43